Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG ≤ 1~* Willing to undergo tumor biopsies from injected and distal lesions~* Must have two biopsy accessible lesions:~  * \* one lesion must be ≥10 mm and \<100 mm in longest diameter, accessible for repeated intratumoral (IT) injection and accessible for baseline and on-treatment biopsies.~    * a second (distal) lesion must be accessible for baseline and on-treatment biopsy and must be distinct from the injected lesion.~   * tumors encasing major vascular structures (i.e., carotid artery or tumors close to other vital organs), are not considered appropriate~Exclusion Criteria:~* Patients who require local palliative measures such as XRT or surgery~* Symptomatic or untreated leptomeningeal disease.~* Presence of symptomatic central nervous system (CNS) metastases~* Impaired cardiac function or clinically significant cardiac disease~* Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.~* Active infection requiring systemic antibiotic therapy.~* Known history of Human Immunodeficiency Virus (HIV) infection.~* Active Epstein-Barr virus (EBV), hepatitis B virus (HBV) or hepatitis C virus (HCV)~* Malignant disease, other than that being treated in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose escalation monotherapy (Type: EXPERIMENTAL): ADU-S100 administered intratumorally on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxicity, progressive disease and/or treatment is discontinued; starting dose 50 micrograms
- Dose escalation combination (Type: EXPERIMENTAL): ADU-S100 administered intratumorally on Days 1 and 8 of each 21-day cycle (starting dose 200 micrograms) and ipilimumab, i.v., (3 mg/kg) on day 1 of each 21-day cycle for the first 4 cycles. Dosing is continued until unacceptable toxicity, progressive disease and/or treatment is discontinued

Based on this trial design, predict the completion outcome and termination type (if applicable).